to identify 5,000 patients
with HFrEF before
the end of 2023
The 2022 HF-iDOC program is a CHFS-led EMR-based quality improvement initiative. The purpose of the program is to ensure that patients with heart failure with reduced ejection fraction (HFrEF) are optimized on foundational therapy as recommended in the 2021 CSS/CHFS guidelines. Under the approved governance framework, the program will leverage EMR data and Pentavere’s AI engine (DARWEN™) to identify patients with confirmed HFrEF and the current treatments received to enable physicians to reduce care gaps. To participate in HF-iDOC, physicians must be utilizing Accuro (QHR Technologies Inc) as their clinical EMR.
• Describe the contemporary landscape of the characteristics and treatment of HFrEF patients, identify practice gaps and challenges faced by cardiologists in the management of HFrEF patients
• Provide a report of participating physicians’ adherence to Canadian guidelines and how they compare to the national average and the U.S.-based CHAMP-HF registry
• Reduce practice gaps, optimize the management of HFrEF patients, and increase the initiation of foundational therapy for patients with HFrEF
This program is powered by Pentavere’s ,breakthrough AI engine, DARWEN™ AI. DARWEN™ AI has been proven and validated to discover high value clinical information buried in clinical text, and will identify patients with HFrEF and current treatments received. By leveraging DARWEN™ AI to mine the totality of the electronic health record, we will be able to identify patients at a greater scale and with higher accuracy compared to standard manual processes.
65 cardiologists participated to date in Phase 1 of the program as of August 2022
+2500 patients identified between September 2020 and August 2022
The protocol of HF-iDOC has been reviewed and approved by an independent ethics review board